Company intelligence / Profile preview

SciVision Biotech

Kaohsiung, Kaohsiung City, Taiwanscivision.com.tw ↗

Ownership: Private
Development stage: Commercial

Overview

SciVision Biotech has developed and commercialized multiple high-end hyaluronic acid-based medical device products across four main fields. The company’s proprietary CHAP technology enables precise control of product characteristics. Their products are marketed internationally and have received regulatory approvals in various regions. Revenue has shown consistent growth over recent years, with significant sales in Asia and expanding presence in Europe and America.

Therapeutic areas: OtherMen's HealthDermatologyRheumatology
Modalities: Hyaluronic acid-based medical devicesDevice
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

HYAJOINT

Commercial

Indications: Joint disorders

Partnerships

International distribution partners; specific names not disclosed publicly

Beyond the preview

Go deeper on SciVision Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciVision Biotech.

Explore the full profile